SFL Appoints Advisory Board

Basel, Switzerland, March 22, 2013 --(PR.com)-- SFL is pleased to announce the constitution of its company Advisory Board. The SFL Advisory Board Members combine a broad range of expertise covering in-depth knowledge of regulatory and policy developments, legal standards, science, medicine and company infrastructures. Thus, they will provide strategic advice and recommendations on the long-term development of SFL and their clients. The Advisory Board will be chaired by Mrs. Silvia Matile-Steiner, former Head Government/Public Affairs at F. Hoffmann-La Roche.

“SFL is witnessing an exciting period of growth and the formation of our Advisory Board will assist us in our future plans,” commented Shayesteh Fürst-Ladani, Managing Director of SFL. “As recognized and experienced practitioners or former practitioners in their fields of expertise their involvement represents an invaluable resource for the company.”

SFL Advisory Board Members include:

Silvia Matile-Steiner, LLM
Mrs. Silvia Matile-Steiner is an expert in public affairs and has extensive professional experience in legal affairs, communications, public relations and government affairs. Previously, she was Head Government/Public Affairs at corporate level at F. Hoffmann-La Roche headquarters. Her work spanned, in particular, diverse research areas such as personalized healthcare, clinical trials and diagnostics. She was in regular contact with EU as well as Swiss key opinion leaders.

Per Helboe, MSc, PhD, DSc
Professor Per Helboe is an expert in regulatory affairs and provides strategic advice on quality- and regulatory-related matters for products. He is Professor in Regulatory Affairs at the University of Copenhagen, Faculty of Health and Medical Sciences, and was Senior Director and Head of the Licensing Division of the Danish Medicines Agency from 2001 until his retirement in 2011.

Bruno Maier, PhD, LLM
Dr Bruno Maier is a qualified lawyer (PhD, Attorney-at-law, LLM) with in-depth practical experience in international commercial law. Dr Maier was Director and General Counsel with world-wide responsibility at F. Hoffmann-La Roche headquarters before his retirement.

Claire Barton, MA MB BChir MRCP PhD FFPM
Dr Claire Barton is a medical oncologist/pharmaceutical physician specializing in the clinical development of products for oncology indications. She is a member of the Oncology Special Interest Group of the Faculty of Pharmaceutical Medicine in the UK, and acts as a Senior Specialty Advisor for pharmaceutical physicians undertaking higher medical training in Pharmaceutical Medicine.

Friedlieb Pfannkuch, MD
Professor Friedlieb Pfannkuch is a qualified pathologist (anatomical pathology) and President of the Swiss Society of Toxicology. He is an expert in non-clinical safety with extensive experience in experimental toxicology and assessment of all stages of drug development.